Ovarian Carcinosarcoma Overview

Save information for later
Sign Up

Learn About Ovarian Carcinosarcoma

What is the definition of Ovarian Carcinosarcoma?
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.
What are the alternative names for Ovarian Carcinosarcoma?
  • Ovarian carcinosarcoma
  • MMMT of the ovary
  • Malignant mixed Müllerian tumor of the ovary
  • Malignant mixed mullerian tumor of the ovary
  • Ovarian malignant mixed Müllerian tumor
  • Ovarian malignant mixed epithelial mesenchymal tumor
Who are the top Ovarian Carcinosarcoma Local Doctors?
Ramez N. Eskander
Dr. Ramez N. Eskander
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Dr. Ramez N. Eskander
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (2.7 mi)
858-657-7000
Languages Spoken:
English
See accepted insurances

Ramez Eskander is a Gynecologic Oncologist and an Oncologist in San Diego, California. Dr. Eskander and is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Splenectomy.

Dr. Michael T. Mchale
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Dr. Michael T. Mchale
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (2.7 mi)
858-249-6753
Languages Spoken:
English
See accepted insurances

Michael Mchale is a Gynecologic Oncologist and an Oncologist in San Diego, California. Dr. Mchale and is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Salpingo-Oophorectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Pratibha S. Binder
Gynecologic Oncology | Oncology
Dr. Pratibha S. Binder
Gynecologic Oncology | Oncology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (2.7 mi)
858-249-6753
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pratibha Binder is a Gynecologic Oncologist and an Oncologist in San Diego, California. Dr. Binder has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Endometrial Cancer, Hysterectomy, and Salpingo-Oophorectomy.

View All Doctors
What are the latest Ovarian Carcinosarcoma Clinical Trials?
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients with Advanced Stage Ovarian Cancer (FRAPPE)
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients with Advanced Stage Ovarian Cancer (FRAPPE)
Enrollment Status: Recruiting
Publish Date: February 07, 2025
Intervention Type: Procedure, Biological
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most le...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center